The company's proprietary platform, PDT, delivers cognitive behavioral therapy to address the underlying causes of type 2 diabetes, heart disease, and other conditions. By changing neural pathways in the brain, lasting behavior changes become possible, leading to improved patient health and reduced healthcare costs. Better Therapeutics is currently enrolling participants for its pivotal trial of BT-001, an investigational therapeutic for type 2 diabetes. Their pipeline includes products for hypertension and high cholesterol. With a focus on delivering first-in-class prescription digital therapeutics, Better aims to fundamentally change the treatment of cardiometabolic diseases. They have a team of experienced biotechnology executives and have received funding from top-tier industry investors. Better Therapeutics went public through a merger with SPAC Mountain Crest Acquisition Corp. in 2021. Their goal is to launch their first product in 2023 and create a portfolio of regulated software products that treat the root causes of disease, improving patient health and providing cost-effective digital behavior therapies.